INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.410
+0.060 (2.55%)
At close: Aug 22, 2025, 4:00 PM
2.370
-0.040 (-1.66%)
After-hours: Aug 22, 2025, 7:58 PM EDT
INmune Bio Market Cap
INmune Bio has a market cap or net worth of $64.07 million as of August 22, 2025. Its market cap has decreased by -54.01% in one year.
Market Cap
64.07M
Enterprise Value
31.15M
1-Year Change
-54.01%
Ranking
Category
Stock Price
$2.41
Market Cap Chart
Since February 4, 2019, INmune Bio's market cap has decreased from $77.82M to $64.07M, a decrease of -17.67%. That is a compound annual growth rate of -2.93%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 22, 2025 | 64.07M | -38.12% |
| Dec 31, 2024 | 103.55M | -48.97% |
| Dec 29, 2023 | 202.92M | 78.35% |
| Dec 30, 2022 | 113.78M | -37.49% |
| Dec 31, 2021 | 182.00M | -21.41% |
| Dec 31, 2020 | 231.57M | 270.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Feb 4, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 638.90B |
| Johnson & Johnson | 431.79B |
| AbbVie | 372.04B |
| UnitedHealth Group | 278.42B |
| Novo Nordisk | 253.97B |
| AstraZeneca | 251.25B |
| Novartis AG | 246.51B |
| Abbott Laboratories | 230.77B |